 SEATTLE, Jan. 08, 2021 GLOBE NEWSWIRE -- Neoleukin Therapeutics, Inc., Neoleukin NASDAQ:NLTX, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration FDA related to its Investigational New Drug IND Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201. 